Clinical evaluation of Delayed graft function (DGF) after kidney transplantation between the vitamin C arm and the placebo
A double-blind, randomized clinical trial with a control group and a placebo group design of 50 patients
Settings and conduct:
- This study will be conducted in a double blinded clinical trial with placebo in the kidney transplantation section of Imam Khomeini Hospital.
- The study will begin after the receipt of the code of ethics and receive the approval of the Ethics Committee.
- Patients undergoing kidney transplants for the first time will be considered for inclusion in the study and admission criteria.
- In case of informed consent, patients will be introduced.
- Patients are divided into two arms of treatment with vitamin C and placebo base on Permuted Block Randomization .
Participants/Inclusion and exclusion criteria:
The first kidney transplantation
Recipient age 14 years and older
Patient informed consent to enter the study
Multi organ transplantation
History of Fauvism
Preemptive kidney transplantation
Patient's dissatisfaction with the continuation of research after entering the study
- Patients in the treatment arm receive 70 mg/kg vitamin C (at least 3 grams) at last hour before transplant surgery. The calculated dose is diluted in 250 ml of sodium chloride solution (0.45%) and infused over an hour before the transplant. In the placebo group, placebo (a saline solution of similar volume) is prescribed at that time.
Main outcome variables:
dialysis in the first week after transplantation